Introduction
============

Breast cancer is the most common cancer in women. Its incidence increases with age; however, very young females represent a special group of patients having special requirements in management because breast cancer in young women is considered aggressive and associated with a poor prognosis.[@b1-bctt-8-053],[@b2-bctt-8-053] Moreover, very young women have higher incidence of advanced stages at diagnosis and poorer 5-year survival than older premenopausal patients.[@b1-bctt-8-053]--[@b3-bctt-8-053] This may be attributed to some worse biologic features including higher incidence of grade 3 tumor, and estrogen receptor (ER)-negative status.[@b4-bctt-8-053],[@b5-bctt-8-053]

There are less publications describing breast cancer characteristics in very young Egyptian women \<35 years, so the aim of the present study was to analyze the clinico-pathological characteristics and describe the current different therapeutic strategies and survival outcome of those very young Egyptian women with breast cancer.

Patients and methods
====================

This study has been approved by the Institutional Research Board of the Faculty of Medicine in Mansoura University with regards to the patients rights and medical ethics. All participating patients provided written informed consent to take part in this study. This is a retrospective study conducted in the Oncology Center--Mansoura University, where the data of all breast cancer patients between September 1, 2006 and August 31, 2015 were reviewed. Among 4,628 patients who were diagnosed with breast cancer during this period, 379 patients were aged ≤35 years. Only 300 young patients had complete registry data, so they were included in the current study, and 79 patients were excluded as they were missing important registry data.

We gathered the clinico-pathological characteristics of those 300 patients who were aged \<35 years at the time of diagnosis. Also, diagnostic and therapeutic procedures, follow-up visits, and survival were recorded.

Hormone receptors status was assessed by immunohistochemical tests for ER and progesterone receptor. The results were interpreted as positive when at least 1% of the invasive carcinoma cells displayed nuclear reactivity. HER2 testing was first performed by immunohistochemical test; score 3+ was interpreted as positive, and score 2+ was considered equivocal and was regarded as positive if confirmed by validated in situ hybridization technique.

Statistics
----------

Data were analyzed on a personal computer running SPSS for windows (Statistical Package for Social Sciences) Release 17. For descriptive statistics of qualitative variables, the frequency distribution procedure was run with calculation of the number of cases and percentages. For descriptive statistics of quantitative variables, the mean, median, range, and standard deviation were used to describe central tendency and dispersion. Survival and progression-free survival analyses were performed using the Kaplan--Meier Product-Limit Estimator.

Results
=======

The incidence of breast cancer in very young Egyptian women (≤35 years) was 8.19% (379/4,628 patients). As regards the results of 300 young patients who had complete registry data, the age ranged between 21 and 35 years, and the mean age was 31 years (±3 standard deviation). The marital status was single in 43 patients (14.3%), and 73 patients (24.3%) had only one child, 70 patients (23.3%) had two children, and 114 patients (38%) had three children. Positive family history of breast cancer was found in 37 patients (12.3%); among them, 13 patients (4.3%) had family history affecting the mother, 15 patients (5%) had family history affecting an aunt, and five patients (1.7%) had family history affecting the mother and aunt; however, negative family history of breast cancer was found in 263 patients (87.7%). Thirteen patients (4.3%) were pregnant at the time of diagnosis. Bilateral presentation had occurred only in one patient (0.33%), and metastatic presentation was shown in 14 patients (4.7%). Patients' characteristics are summarized in [Table 1](#t1-bctt-8-053){ref-type="table"}.

The histopathologic types were invasive ductal carcinoma in 243 patients (81%), invasive lobular carcinoma in 39 patients (13%), and medullary carcinoma in ten patients (3.3%), and other types were recorded in eight patients (2.7%). Associated in situ components were recorded in 54 patients (18%). Tumor grading showed that grades 1, 2, and 3 were represented in nine (3%), 199 (66.3%), and 92 (30.7%) of the tumors, respectively. Tumor size ranged between 0.6 and 12 cm (the median was 3 cm), the number of resected lymph nodes ranged between eight and 32 (the median was 13), and the number of positive lymph nodes ranged between zero and 28 (the median was three). Tumor pathologic characteristics are summarized in [Table 2](#t2-bctt-8-053){ref-type="table"}.

A total of 176 (58.7%) patients' tumors were hormone receptor positive, and among 217 patients who had the HER2 test, 82 patients (37.8%) were HER2 positive and 135 patients (62.2%) were HER2 negative. Ki 67 percentage ranged between 3% and 66% (median was 35%). Analysis of breast cancer subtypes included 216 cases with complete data. Only seven patients (3.2%) presented with luminal A-like breast cancer. The majority of patients presented with luminal B-like subtype (107 cases, 49.5%). HER2 overexpression in non-luminal type was found in 45 cases (20.8%). Interestingly, triple-negative subtype was found in 57 patients (26.4%). Tumor biomarker characteristics are summarized in [Table 3](#t3-bctt-8-053){ref-type="table"}.

As regards the treatment options ([Table 4](#t4-bctt-8-053){ref-type="table"}), all patients received chemotherapy. Neoadjuvant therapy was administrated in 132 patients (44%), and pathologic complete response was achieved in 21 patients (15.9%).

Surgery was performed in non-metastatic patients (N=286); modified radical mastectomy was done in 134 patients (46.9%), conservative breast surgery was done in 65 patients (22.7%), and conservative (sparing) mastectomies with immediate breast reconstruction using latissimus dorsi flaps were done in 87 (30.4%) patients; among them, 70 patients (24.5%) had nipple-sparing mastectomy, and 17 patients (5.9%) had skin-sparing mastectomy.

Radiotherapy was administrated in 267 patients (89%), and endocrine therapy was administrated in 176 patients (58.7%); 126 patients (42%) received Tamoxifen, and 50 patients (16.7%) received Tamoxifen plus leutenizing hormone-releasing hormone. Trastuzumab was administrated in 80 patients among those 82 patients with positive HER2.

The median disease-free survival (DFS) was 61 months (95% confidence interval 44--78 months); the 3-year and 5-year DFS was 58% and 50%, respectively ([Figure 1](#f1-bctt-8-053){ref-type="fig"}). The 3-year and 5-year overall survival (OS) was 88% and 68%, respectively ([Figure 2](#f2-bctt-8-053){ref-type="fig"}).

Discussion
==========

The definition of a young woman varies in the breast oncology field. Most authors are defining women under either age 35 or 40 years as "young".[@b6-bctt-8-053] However, in the current study, we used the term very young referring to those women who were aged ≤35 years while preserving the term young for those women under the age of 40 years.

Although breast cancer is the most common cancer in women, its incidence among young women widely varies in literature. Approximately 7% of women are diagnosed with breast cancer below the age of 40.[@b7-bctt-8-053] It may differ according to race. In Finland, during the year 2008, only 1% of the patients were younger than 35 years,[@b8-bctt-8-053] while 2.7% of young Japanese patients were diagnosed with breast cancer (\<35 years).[@b9-bctt-8-053] Among American women who were diagnosed with breast cancer between 2000 and 2005, 6.6% of them were diagnosed before age 40, and 2.4% diagnosed before age 35.[@b7-bctt-8-053] In People's Republic of China, the proportion of young age-onset breast cancer (35 years old or younger) was very high, reaching 11.1% of patients.[@b10-bctt-8-053]

In the current study, we reported an incidence of 8.19% who were aged \<35 years among 4,628 patients who were diagnosed with breast cancer over 10 years (2006--2015) in the Oncology Center -- Mansoura University, Egypt. However, previous Egyptian retrospective study carried out on 1,009 female patients with operable non-metastatic primary breast cancer who were treated at the Radiotherapy Department of the National Cancer Institute of Cairo, Egypt, between 1999 and 2003, showed that 20.7%[@b11-bctt-8-053] were young Egyptian patients (\<35 years) Another Egyptian Study of 6,996 patients with breast cancer over 10 years (1999--2008) in Gharbiah, Egypt, showed that the overall incidence among patients aged \<40 years was 17.2%.[@b12-bctt-8-053]

Breast cancer in younger women is mostly diagnosed at a later stage, and is of higher grade, has less ER positivity, and has a greater chance of recurrence.[@b4-bctt-8-053],[@b13-bctt-8-053]--[@b17-bctt-8-053]

The ER negative disease in the current study was 51% which was higher than the figure recorded (40%) in the Finnish study which was carried on 214 patients (≤35 years).[@b19-bctt-8-053] However, positive HER2 in our study was seen in 37.8% which was similar to the figure recorded (34%) in the Finnish study.[@b18-bctt-8-053]

The involvement of axillary lymph nodes in young women when compared with older patients is high.[@b19-bctt-8-053] A Nepali study with 944 breast cancer patients identified that axillary lymph nodes were positive in 73% of younger patients (\<40 years) and 59% of older patients (*P*=0.002).[@b20-bctt-8-053] In our study, the rate of axillary lymph nodes involvement was 75.7%. These findings indicate the severity and aggressiveness of the disease in this age group.

Similar to other studies, the most frequent histological type of breast cancer in young women was infiltrating ductal carcinoma.[@b20-bctt-8-053]--[@b22-bctt-8-053] In the current study, its incidence was 81%; however, it was 95% in an analytical Tunisian retrospective survey among women with breast cancer younger than 35 years.[@b23-bctt-8-053]

In the present study, younger women were more likely to develop grade 2 (66.3%) and grade 3 (30.7%) tumors. This is similar to the study of Bouzid et al which found that grade 2 and 3 tumors were present in 41.1% and 37.1% of cases, respectively.[@b23-bctt-8-053]

As worldwide, young Egyptian females with breast cancer are generally treated similarly to their older counterparts; for example, the neoadjuvant chemotherapy is given to those who present with locally advanced breast cancer, and the surgical options are either mastectomy (with or without immediate breast reconstruction) or breast-conserving surgery followed by radiotherapy. As in older women, factors affecting surgical decisions include tumor size, location, ability to achieve a free safety margin with good cosmetic outcome, and patient preference. In the current study, the percentage of breast-conserving surgery was 22.7% versus 77.3% for mastectomy. This may be attributed to that the relatively local advanced disease is present among those patients and most of the young females are worried about intramammary recurrence, so they prefer to do mastectomy.

Adjuvant chemotherapy is used more frequently in young women than in older women,[@b9-bctt-8-053] probably because of longer life expectancy and better tolerability to aggressive treatments and documented survival advantages compared to women not treated with adjuvant therapy.[@b24-bctt-8-053] In our study, all patients received chemotherapy.

But still, the younger patients received more mastectomies even with small tumors, more axillary surgery, and more chemotherapy. This may be due to the higher portion of additional ductal carcinoma in situ in the young cohort, a higher percentage of patients with history of breast cancer in the family, and perhaps even a higher need for maximal safety of therapy by the treating clinician.[@b25-bctt-8-053]

Breast cancer in young women is thought to have an aggressive biological behavior and is associated with a poor prognosis and less favorable survival.[@b1-bctt-8-053],[@b2-bctt-8-053] A Finnish study, which included 214 patients aged ≤35 years with breast cancer during 1997--2007, revealed a DFS of 70% (the median disease free interval was 30 months, and range was 8--103 months), and the 5-year OS was 80%.[@b18-bctt-8-053] However, in the current study, the 5-year DFS was 50% (the median disease-free interval was 61 months, and range was 44--78 months), and the 5-year OS was 68%. The reason for the poorer DFS and OS survival of young women in our study compared to the Finnish study seems to be different tumor characteristics and treatments.

Conclusion
==========

Very young patients with breast cancer in Egypt constitute a unique group of patients as they have special tumor characteristics. This group has more advanced presentation, with much more aggressive biologic behavior, and has a significantly higher malignant axillary lymph node involvement. So, therapy for each young patient with breast cancer has to be evaluated carefully and individually, and the treatment strategies have to be tailored in a very precise manner.
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![The median DFS was 61 months (95% confidence interval 44--78 months); the 3-year and 5-year DFS were 58% and 50%, respectively.\
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![The 3-year and 5-year OS were 88% and 68%, respectively.\
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###### 

Patients' characteristics

  Personal data               Item              N =300   \%
  --------------------------- ----------------- -------- ------
  Marital status              Single            43       14.3
                              One child         73       24.3
                              Two children      70       23.3
                              Three children    114      38
  Family history              No                263      87.7
                              Mother            13       4.3
                              Aunt              15       5
                              Sister            4        1.3
                              Mother and aunt   5        1.7
  Pregnancy at presentation   Yes               13       4.3
                              No                287      95.7

**Abbreviation**: No, number.

###### 

Tumor pathologic characteristics

  Tumor characteristics           Item         No=300          \%
  ------------------------------- ------------ --------------- -----------
  Side                            Rt           158             52.7
                                  Lt           141             47
                                  Bilateral    1               0.3
  T                               1            46              15.3
                                  2            175             58.3
                                  3            40              13.3
                                  4            39              13
  N                               0            73              24.3
                                  1            81              27
                                  2            65              21.7
                                  3            81              27
  M                               0            286             95.3
                                  1            14              4.7
  Pathology types                 IDC          243             81
                                  ILC          39              13
                                  Medullary    10              3.3
                                  Other        8               2.7
  Associated in situ components   No           246             82
                                  Yes          54              18
  Grade                           1            9               3
                                  2            199             66.3
                                  3            92              30.7
                                  **Median**   **Mean (SD)**   **Range**
  Tumor size                      3.0          3.9 (2.1)       0.6--12.0
  LN positive                     3            5 (6)           0--28
  LN resected                     13           14 (5)          8--32

**Abbreviations:** Rt, right; Lt, left; T, tumor; N, node; M, metastasis; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; SD, standard deviation; LN, lymph node; No, number.

###### 

Tumor biomarker characteristics

  Biomarkers             Item                  No              \%
  ---------------------- --------------------- --------------- -----------
  ER                     Negative              153             51
                         Positive              147             49
  PR                     Negative              145             48.3
                         Positive              155             51.7
  Hormone receptors      Negative              124             41.3
                         Positive              176             58.7
  HER2 (217 cases)       Negative              135             62.2
                         Positive              82              37.8
  Subtypes (216 cases)   Luminal A-like        7               3.2
                         Luminal B-like        107             49.5
                         HER2 overexpression   45              20.8
                         Triple-negative       57              26.4
                         **Median**            **Mean (SD)**   **Range**
  Ki 67 (%)              35                    35 (21)         3--66

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation; No, number.

###### 

Treatment options

  Management                                           Item                                                          No    \%
  ---------------------------------------------------- ------------------------------------------------------------- ----- ------
  Surgery (286 non-metastatic cases)                   MRM                                                           134   46.9
                                                       Conservative mastectomies + immediate breast reconstruction   87    30.4
                                                       NSM + LD                                                      70    24.5
                                                       SSM + LD                                                      17    5.9
                                                       BCS                                                           65    22.7
  Chemotherapy                                         Metastatic                                                    14    4.7
                                                       Neoadjuvant                                                   132   44
                                                       Adjuvant                                                      154   51.3
  Complete PCR after neoadjuvant therapy (132 cases)   No                                                            111   84.1
                                                       Yes                                                           21    15.9
  Radiotherapy                                         No                                                            33    11
                                                       Yes                                                           267   89
  Endocrine therapy                                    No                                                            124   41.3
                                                       Tamoxifen                                                     126   42
                                                       Tamoxifen + LHRH                                              50    16.7
  Trastuzumab (82 positive cases)                      No                                                            2     2.4
                                                       For 1 year                                                    80    97.6

**Abbreviations:** MRM, modified radical mastectomy; NSM, nipple-sparing mastectomy; LD, latissimus dorsi; SSM, skin-sparing mastectomy; BCS, breast-conserving surgery; PCR, pathologic complete response; LHRH, leutenizing hormone-releasing hormone; No, number.
